Sarcomas

R. Lor Randall, MD, FACS, outlines how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.

R. Lor Randall, MD, FACS, discusses AI in musculoskeletal tumor diagnosis, surgical planning and robotics, and validation of AI tools.

SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.

R. Lor Randall, MD, FACS, discusses novel precision surgery techniques that are making progress in sarcoma care.

The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.

SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.

R. Lor Randall, MD, FACS, discusses what’s next for TGCT treatment and the most important developments to come out of 2026 TGCT Master Workshop.

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Sarcoma management demands coordinated, subtype-specific care and treatment sensitivities delivered by a dedicated multidisciplinary team.

Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.

Ris-rez improved PFS vs chemotherapy in the ARTEMIS-011 trial for relapsed/refractory osteosarcoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA set a PDUFA target action date of April 28, 2027, for varegacestat in desmoid tumors.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes such as EFS.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

The FDA has accepted a BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027.

Varegacestat reduced the risk of disease progression or death by 84% vs placebo in progressing desmoid tumors.

Circulating tumor DNA analyses from the phase 1/1b StrateGIST-1 trial also support baseline ctDNA detectability as a potentially prognostic marker in this population.

Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.

Bezuclastinib plus sunitinib decreased the risk of progression or death by 50% compared with sunitinib monotherapy in GIST.

The FDA has accepted for review an NDA for bezuclastinib plus sunitinib in imatinib-pretreated GISTs, with a PDUFA date of November 30, 2026.